OliX Pharmaceuticals, Inc (KOSDAQ:226950)
South Korea flag South Korea · Delayed Price · Currency is KRW
111,600
-2,600 (-2.28%)
Sep 18, 2026, 3:30 PM KST

OliX Pharmaceuticals Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-14,030-15,743-40,659-19,102-19,495-29,715
Depreciation & Amortization
2,3452,4542,6262,6422,0751,630
Loss (Gain) From Sale of Assets
-273.84-256.32-1,64987.48-10,506-
Loss (Gain) From Sale of Investments
13.1876.72-349.21-439.0135.02-11.87
Loss (Gain) on Equity Investments
--8,223900.91--
Stock-Based Compensation
5,7202,7771,1631,2261,5941,932
Other Operating Activities
-25,697-14,9194,396668.744,0664,750
Change in Accounts Receivable
12,415-5,2653,558-3,567-73.03-
Change in Inventory
86.6157.55-85.85188.76-283.04-69.96
Change in Other Net Operating Assets
-10,66114,818-5,268-3,774-8,0952,431
Operating Cash Flow
-30,082-15,900-28,045-21,168-30,683-19,054
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-1,464-1,262-13,465-8,826-2,233-1,290
Sale of Property, Plant & Equipment
672.86605.43,24854.34110.0430.6
Cash Acquisitions
-----1,387-
Sale (Purchase) of Intangibles
-767.67-595.53-170.16-239.11-301.41164.38
Sale (Purchase) of Real Estate
134.6134.61,092---24,744
Investment in Securities
-80,916-104,35310,02143,152-51,11541,373
Other Investing Activities
361.75528.11247.85224.94-56.54-129.21
Investing Cash Flow
-82,107-104,942973.5634,366-54,76415,473

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-1,320----
Long-Term Debt Issued
-10,12319,70023,600-20,000
Total Debt Issued
-11,44319,70023,600-20,000
Short-Term Debt Repaid
--676----
Long-Term Debt Repaid
--8,902-1,143-30,057-786.04-382.65
Total Debt Repaid
-5,411-9,578-1,143-30,057-786.04-382.65
Net Debt Issued (Repaid)
-5,4111,86618,557-6,457-786.0419,617
Issuance of Common Stock
106,8897,511-474.65-706.28
Other Financing Activities
-530.04-539.23-15.29-127.81-166.041,732
Financing Cash Flow
215,950123,83918,541-6,11056,04826,555

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-89.18-521.87430.69-35.09-7.8732.94
Net Cash Flow
103,6722,475-8,0997,052-29,40623,008

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-31,547-17,161-41,510-29,995-32,916-20,344
Free Cash Flow Growth
------
Free Cash Flow Margin
-231.35%-117.01%-731.17%-175.77%-353.16%-553.66%
Free Cash Flow Per Share
-1490.26-872.60-2464.51-2078.73-2402.08-1486.45
Levered Free Cash Flow
-12,631-17,224-22,189-35,664-19,6353,426
Unlevered Free Cash Flow
-11,936-16,087-19,275-33,482-17,8034,945

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
1,1141,229544.131,225785.3-
Cash Income Tax Paid
230.471,665-224.031,516311.2755.25
Change in Working Capital
1,8409,711-1,796-7,153-8,4512,361